BAT trades at deep value with ~8% dividend yield as the New Categories business (Vuse, Velo, glo) approaches profitability inflection. US menthol ban delay and continued ITC India stake monetization provide tailwinds. ESG-driven selling has likely exhausted, and the recategorization toward reduced-risk products is gaining FDA recognition. Free cash flow supports both deleveraging and shareholder returns.
Signals scoped to GB · Company-specific tagging coming soon.